ARTICLE | Management Tracks

Obsidian fills CEO, CDO roles with Iovance vets

Plus: Jami Rubin joins Arch, and updates from Exo, Harbinger, Twist and more

May 23, 2023 11:14 PM UTC

Cell and gene therapy company Obsidian Therapeutics Inc. hired Madan Jagasia as CEO and Parameswaran Hari as chief development officer. Both were most recently at Iovance Biotherapeutics Inc. (NASDAQ:IOVA), where Jagasia was EVP, medical affairs, and Hari was SVP, clinical science.

Jami Rubin became a venture partner at Arch Venture Partners. Rubin was CFO at EQRx Inc. (NASDAQ:EQRX) and is a 20-plus-year veteran of Goldman Sachs, where she covered the biopharma industry as an equity analyst...